ClinicalTrials.gov
public full text
Public Domain
Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)
Study ADX-324-302 is an extension study for participants who complete the Phase 3 ADX-324-301 trial. The extension study will provide information about the safety and efficacy of additional dosing of ADX-324 in participants with Type I and Type II hereditary angioedema (HAE). The study will also include pharmacodynamic (PD), pharmacokinetic (PK), and health-related quality of life (HRQoL) measurements.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Phase 2 in Adult Subjects With Hereditary Angioedema#903473
- A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema#1186264
- A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease#1382131
- Effect of Intravenous Acetadote on Incidence of Contrast Induced Nephropathy#1231658
- Autonomic Nervous System Profile in Hereditary Angioedema#1408929
Record · ID 1409431
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive